05.05.11
InterHealth Nutraceuticals, Inc. has launched Zychrome, a new form of chromium that has been shown in a randomized, double-blind, placebo-controlled study to significantly decrease insulin resistance and fasting insulin levels in diabetic subjects. Reductions of 30% were seen for both insulin parameters after three months of supplementation. Zychrome also significantly decreased inflammatory cytokine TNF-α levels by 21%. Reductions in this metabolic marker may help lead to normal insulin and blood sugar control. Zychrome is a unique form of chromium, niacin and L-cysteine called chromium dinicocysteinate, according to the company.